- A cohort study assessed the impact of persistent prostate-specific antigen (PSA) levels following radical prostatectomy (RP) on mortality risk.
- Higher pre-RP PSA level was significantly associated with reduced all-cause mortality and prostate cancer-specific mortality risk among patients with persistent PSA levels.
- The study noted the importance of extending the monitoring period for PSA levels to avoid premature treatment decisions.
- The study included 43,298 patients treated with RP between 1992 and 2020 at two academic centers.
- Among the 30,461 patients in the discovery cohort, the median age was 64 years, while the validation cohort of 12,837 patients had a median age of 59 years.
Source: JAMA Oncology
